E Fund Management Co., Ltd. Fibrogen Inc Transaction History

E Fund Management Co., Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $13,854 - $114,562	5,564 Added 39.88%	19,515 $53,000
Q1 2023 May 11, 2023	BUY	$15.95 - $25.18 $5,454 - $8,611	342 Added 2.51%	13,951 $260,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $27,243 - $36,399	-2,053 Reduced 13.11%	13,609 $218,000
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $20,303 - $26,002	-1,781 Reduced 10.21%	15,662 $204,000
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $28,099 - $45,865	3,539 Added 25.45%	17,443 $184,000
Q1 2022 May 12, 2022	BUY	$12.02 - $16.79 $167,126 - $233,448	13,904 New	13,904 $167,000
Q4 2021 Feb 11, 2022	SELL	$9.93 - $15.39 $150,945 - $233,943	-15,201 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $114,596 - $299,886	11,257 Added 285.42%	15,201 $155,000
Q1 2021 May 12, 2021	BUY	$31.0 - $55.72 $122,264 - $219,759	3,944 New	3,944 $136,000

46.8M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $53.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.